The pharmaceutical major Aurobindo Pharma has received authorization from Medicines Control Council (MCC) to make and promote nine products in the South African market, with an estimated market size of 165 million rand.

The nine products for which the company has received MCC approval comprise Auro - Lisinopril Co, Auro-Amlodipine, Auro - Finasteride, Zinoxime, Zolid, Yomax, Lazivir, Lisinozide and Profina.

In a declaration, the company said that it now has 31 marketing authorizations sanctioned by MCC.

Headquartered in Hyderabad, Aurobindo Pharma is the maker of generic pharmaceuticals and active pharmaceutical ingredients. The company has already got approvals for several facilities from leading regulatory agencies including US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.

The company has a robust product portfolio, which is spread over 6 major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals and anti-allergics. It is marketing these products internationally in more than 100 countries.

At 1:21 pm, the shares of JBM Auto lost 2.8% at Rs 328.10 on the Bombay Stock Exchange (BSE).